A-620223
Based on 1 publication(s) in Google Scholar
A-620223 is a PARP-1 inhibitor with a Ki of 8 nM against PARP-1 and EC50 of 3 nM in a whole cell assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) (HY-17364) and in an MX-1 breast xenograph model in combination with Cisplatin (HY-17394). A-620223 can be used for the studies of melanoma and breast cancer.
For research use only. We do not sell to patients.
- Purity: 96.09%
- CAS No.: 272769-49-0
- Formula: C16H22N4O
- Molecular Weight:286.37
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) A-620223
More
Biological Activity
|
PARP-1 8 nM (Ki) |
| Species | Dose | Route | Vss | F | CL | Cmax | AUC | T1/2 |
|---|---|---|---|---|---|---|---|---|
| Dog[1] | 4.1 mg/kg | p.o. | 3.6 L/kg | 82 % | 0.9 L/h/kg | 1 μg/mL | 3.7 μg·h/mL | / |
| Mice[1] | 10 mg/kg | p.o. | 9.1 L/kg | 63 % | 5.3 L/h/kg | 0.4 μg/mL | 1.2 μg·h/mL | / |
| Mice[1] | 3 mg/kg | i.v. | / | / | / | / | / | 1.2 h |
| Monkey[1] | 4.1 mg/kg | p.o. | 4.9 L/kg | 32 % | 2 L/h/kg | 0.2 μg/mL | 0.7 μg·h/mL | / |
| Rat[1] | 4.1 mg/kg | p.o. | 10.7 L/kg | 48 % | 2.9 L/h/kg | 0.8 μg/mL | 0.7 μg·h/mL | / |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B16F10 melanoma model and MX-1 breast cancer xenograft model established in C57BL/6 mice and female SCID mice[1]
-
Dosage:1, 12.5 and 25 mg/kg (melanoma model); 5 and 25 mg/kg (breast cancer model)
-
Administration:Subcutaneous injection (s.c.), successive administration for 7-14 days
-
Result:Showed excellent potentiation of cytotoxic agents in two subcutaneous, murine tumor models.
Chemical Information
-
CAS No. 272769-49-0
-
Appearance Solid
-
Molecular Weight 286.37
-
Formula C16H22N4O
-
SMILES
CCCN(CC1)CCC1C2=NC3=C(C(N)=O)C=CC=C3N2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz